Graham Collins, Associate Professor, Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared a post on X:
“Nivo-AVD vs BV-AVD in older pts (60+) with Hodgkin. S1826 data. 99 eligible pts. 2y PFS
• 89% Nivo-AVD
• 64% BV-AVD
55% discontinued BV, 14% Nivo
NRM 16% BV-AVD, 6% Nivo-AVD
Transformational. If only we had access.”
Title: Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
Authors: Sarah C. Rutherford, Hongli Li, Alex F. Herrera, Michael LeBlanc, Sairah Ahmed, Kelly Davison, Susan K. Parsons, Joseph M. Unger, Anamarija M. Perry, Carla Casulo, Nancy L. Bartlett, Joseph M. Tuscano, Brian T. Hess, Pallawi Torka, Pankaj Kumar, Ryan Jacobs, Joo Y. Song, Sharon M. Castellino, Brad Kahl, John P. Leonard, Sonali M. Smith, Jonathan W. Friedberg, Andrew M. Evens
More Posts Featuring Hodgkin Lymphoma on OncoDaily.